PUBLISHER: DataM Intelligence | PRODUCT CODE: 1290434
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1290434
Global Blood Cancer Drugs Market - 2023-2030
Market Overview
The Global Blood Cancer Drugs Market size reached US$ 63 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 113.5 billion by 2030. The Global Blood Cancer Drugs Market is expected to exhibit a CAGR of 7.8% during the forecast period 2023-2030. The key market trend is the rapid advancements of immunotherapies.
For instance, in April 2023, Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced the launch of Strata Select, a first-of-its-kind molecular profiling test for patients with advanced cancer.
The new diagnostic test features the Immunotherapy Response Score, a novel multivariate predictive biomarker algorithm for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy benefit. Blood cancer drugs encompass diverse therapeutic interventions, including chemotherapy, targeted therapies, immunotherapies, and supportive care medications, designed to specifically target and inhibit the growth of cancerous cells in the blood and bone marrow.
These drugs aim to disrupt abnormal cellular processes, suppress cancer cell proliferation, induce apoptosis, and restore normal blood cell production and function.
The blood cancer drugs market is driven by factors such as the increasing prevalence of blood cancers, advancements in cancer research, development of targeted therapies, immunotherapies, and personalized medicine.
For instance, in May 2023, Amneal Pharmaceuticals, Inc. announced the commercial launch of FYLNETRA, a biosimilar referencing Neulasta in a pre-filled single-dose syringe. FYLNETRA is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy.
Market Dynamics
Increasing prevalence of blood cancers
The increasing prevalence of blood cancers is the major factor driving the market share during the forecast period. Blood cancers, particularly certain types such as leukemia, lymphoma, and multiple myeloma, are more commonly diagnosed in older individuals. As the global population continues to age, the overall incidence of blood cancers increases.
Exposure to certain environmental factors and unhealthy lifestyle choices can increase the risk of developing blood cancers. Environmental factors include exposure to radiation, certain chemicals, pesticides, and industrial pollutants. Unhealthy behaviors like smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to the development of blood cancers.
High cost and side effects of treatment
Blood cancer drugs often come with a high price tag due to the extensive research and development efforts involved and the complexity of manufacturing and testing processes. The cost of these drugs can pose a significant financial burden on patients, healthcare systems, and payers. The high cost of treatment can impact market growth and hinder patient access to blood cancer drugs.
Blood cancer drugs can cause various adverse effects, including fatigue, nausea, vomiting, hair loss, immunosuppression, and organ toxicity. These side effects can significantly impact patients' quality of life and treatment adherence. Managing side effects and developing supportive care measures are important considerations in improving patient outcomes and market acceptance of blood cancer drugs.
COVID-19 Impact Analysis
The COVID-19 pandemic has profoundly impacted the healthcare industry, including the blood cancer drugs market. Blood cancer patients are considered vulnerable due to their compromised immune systems and higher risk of severe COVID-19 outcomes. As a result, patient management strategies have been modified to minimize exposure to the virus.
Some research activities related to blood cancer drugs may have been temporarily deprioritized or redirected towards COVID-19-related projects. This shift in research focus may impact the pace of drug development and innovation in the blood cancer drugs market
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict has significantly impacted the blood cancer drugs market. The conflict may disrupt research and development collaboration in institutions and pharmaceutical companies. Collaborative efforts in drug discovery, clinical trials, and scientific exchange may be hampered, impacting the pace of innovation and development of new blood cancer drugs.
The conflict between Russia and Ukraine may impact international collaborations and investments in the blood cancer drugs market. Companies and investors may approach these markets with caution due to geopolitical risks and uncertainties, potentially leading to a slowdown in investments and collaborations.
Segment Analysis
The Global Blood Cancer Drugs Market is segmented based on cancer type, therapy type, route of administration, End User, and region.
Based on cancer type, the leukemia segment is expected to dominate the market share
The leukemia market will hold 35.8% of the global blood cancer drugs market share in 2022. Leukemia has been the subject of extensive research and development efforts in the field of blood cancer drugs. Significant advancements have been made in understanding the molecular basis of different leukemia subtypes, leading to the development of targeted therapies and immunotherapies.
For instance, in May 2023, Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA, a leading provider of commercialization services to the life science industry, announced the commercial launch of the company's oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older.
Geographical Analysis
North America holds the largest market share due to the presence of key players and advanced healthcare infrastructure
North America holds the 41.3% market share for the blood cancer drugs market in 2022 due to the presence of key players and advanced healthcare infrastructure in the region. North America boasts advanced healthcare infrastructure, including well-established hospitals, research institutions, and oncology centers.
The region has a robust healthcare system that facilitates access to diagnosis, treatment, and follow-up care for blood cancer patients. The availability of state-of-the-art medical facilities, advanced diagnostic technologies, and specialized healthcare professionals supports the demand for blood cancer drugs and drives market growth.
Competitive Landscape
The major global players in the market include: Amgen Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Ltd, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead Sciences Inc., Daiichi Sankyo Company Ltd, and UCB SA.
Why Purchase the Report?
- To visualize the Global Blood Cancer Drugs Market segmentation based on cancer type, therapy type, route of administration, End User, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of blood cancer drugs market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Blood Cancer Drugs Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Cancer Type
- 3.2. Snippet by Therapy Type
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by End User
- 3.5. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing prevalence of blood cancers
- 4.1.1.2. Development of targeted therapies and immunotherapies
- 4.1.2. Restraints
- 4.1.2.1. High cost of treatment
- 4.1.2.2. Side effects associated with treatment
- 4.1.3. Opportunity
- 4.1.3.1. Advancements in cancer research
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturer's Strategic Initiatives
- 6.6. Conclusion
7. By Cancer Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 7.1.2. Market Attractiveness Index, By Cancer Type
- 7.2. Leukemia*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Myeloma
- 7.4. Non-Hodgkin Lymphoma
- 7.5. Hodgkin Lymphoma
8. By Therapy Type
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 8.1.2. Market Attractiveness Index, By Therapy Type
- 8.2. Chemotherapy*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Radiation Therapy
- 8.4. Immunotherapy
- 8.5. Targeted Therapy
- 8.6. Others
9. By Route of Administration
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
- 9.2. Oral*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Parenteral
- 9.4. Others
10. By End User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Specialty Clinics
- 10.4. Ambulatory Surgical Centers
- 10.5. Others
11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. The U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. The UK
- 11.3.7.3. France
- 11.3.7.4. Italy
- 11.3.7.5. Spain
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.7.1. Brazil
- 11.4.7.2. Argentina
- 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
13. Company Profiles
- 13.1. Amgen Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. AstraZeneca Plc
- 13.3. Takeda Pharmaceutical Company Ltd
- 13.4. Bayer AG
- 13.5. Celgene Corporation
- 13.6. Eli Lilly
- 13.7. Bristol-Myers Squibb Company
- 13.8. Gilead Sciences Inc.
- 13.9. Daiichi Sankyo Company Ltd
- 13.10. UCB SA
LIST NOT EXHAUSTIVE
14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
